Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
26 august 2017, Barcelona, Spain
ESC 2017: New approaches to targeting residual cardiovascular risk
Read full report..
R3i editorial
12 July 2018

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
The clinical gap for managing residual cardiovascular risk: will new approaches make the difference?Read more...

In 2013, the Residual Risk Reduction Initiative published a second ‘call to action’ on residual cardiovascular risk, following the initial paper in 2008. Five years later, are we any closer to defining management approaches that effectively reduce this risk?
Over this time, we have, however, gained a number of important insights. With respect to lipid-related residual cardiovascular risk, it is now clear that even lowering low-density lipoprotein cholesterol (LDL-C) to levels below those recommended by current guidelines does not eliminate this risk...
landmark study
12 July 2018

Lipoprotein(a) and residual cardiovascular risk

It is well recognised that residual cardiovascular risk persists despite well managed LDL-C levels with statin therapy.1 Even the addition of novel LDL-lowering agents resulting in very low LDL-C levels fails to eliminate this risk.2 Perhaps the strongest evidence to date for contributors to lipid-related...
focus on...
12 July 2018

APOA5 genetic variability, triglycerides and coronary heart disease risk in Chinese subjectsRead more...

Genetic insights into the regulation of triglyceride-rich lipoproteins has offered alternative therapeutic approaches. In over 15 years since its discovery, there is now accumulating evidence that APOA5 is an important determinant of plasma triglycerides.1 Loss-of-function APOA5 variants have been shown to be associated with reduced...
Looking to the American College of Cardiology Scientific Sessions 2018
67th Annual Scientific Sessions of the American College of Cardiology, 10-12 March, Orlando, USA.
Read more..
This year’s Scientific Sessions offers new insights from CANTOS and COMPASS, as well as novel approaches targeting elevated triglycerides and lipoprotein(a). Added to this, the second of the cardiovascular outcomes studies with PCSK9 monoclonal antibody therapy, ODYSSEY Outcomes with alirocumab in patients with a recent acute coronary syndrome, is keenly anticipated.
recent publication

News from the XVIIIth International Symposium on Atherosclerosis, 9-12 June, 2018, Toronto, Canada:
New SPPARM?, pemafibrate, a focus of interest in the poster sessionsRead more...

A number of posters added to the information about this novel lipid-modifying agent. As a follow-up to the clinical study...
recent publication

PREDIMED Trial revisited

The PREDIMED study has been retracted, and then republished after concerns were raised about baseline data distributions which may have...
recent publication

Do genome-editing technologies have a role in managing atherogenic dyslipidaemia?Read more...

A state-of-the art review suggests potential for novel genome-editing techniques, such as CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR-associated 9),...
recent publication

Dyslipidemia International Survey-China survey highlights atherogenic dyslipidaemia

In the Dyslipidemia International Survey-China survey, over 50% of patients had persistent atherogenic dyslipidaemia despite attainment of low-density lipoprotein cholesterol...
recent publication

AIM-HIGH: post hoc analysis suggests benefit in atherogenic dyslipidaemia

The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial did not...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.